CA3015309C - Composes de carbapeneme - Google Patents

Composes de carbapeneme Download PDF

Info

Publication number
CA3015309C
CA3015309C CA3015309A CA3015309A CA3015309C CA 3015309 C CA3015309 C CA 3015309C CA 3015309 A CA3015309 A CA 3015309A CA 3015309 A CA3015309 A CA 3015309A CA 3015309 C CA3015309 C CA 3015309C
Authority
CA
Canada
Prior art keywords
optionally substituted
date
cooh
substituted
f2hc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3015309A
Other languages
English (en)
Other versions
CA3015309A1 (fr
Inventor
Gopalan Balasubramanian
Maneesh Paul-Satyaseela
Chidambaram Venkateswaran Srinivasan
Sridhar Ramanathan Iyer
Hariharan Periasamy
Venkatesan Parameswaran
Bharani THIRUNAVUKKARASU
Prabhakar Rao Gunturu
Manjula Devi Deshkumar
Venkateshwarlu JAKKALA
Ravi Nargund
Michael Wayne Miller
Sheo Singh
Shuzhi DONG
Hongwu Wang
Katherine Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orchid Pharma Ltd
Merck Sharp and Dohme LLC
Original Assignee
Orchid Pharma Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orchid Pharma Ltd, Merck Sharp and Dohme LLC filed Critical Orchid Pharma Ltd
Publication of CA3015309A1 publication Critical patent/CA3015309A1/fr
Application granted granted Critical
Publication of CA3015309C publication Critical patent/CA3015309C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés de carbapénème, leurs stéréoisomères, et leurs sels ou N-oxydes pharmaceutiquement acceptables, qui peuvent être utiles pour traiter les infections bactériennes, en particulier les infections bactériennes pharmacorésistantes, ainsi que des procédés de préparation des composés, des compositions pharmaceutiques de ces composés et leur utilisation dans le traitement d'une infection bactérienne.
CA3015309A 2016-03-16 2017-03-15 Composes de carbapeneme Active CA3015309C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201641009127 2016-03-16
IN201641009127 2016-03-16
PCT/IN2017/000060 WO2017158616A1 (fr) 2016-03-16 2017-03-15 Composés de carbapénème

Publications (2)

Publication Number Publication Date
CA3015309A1 CA3015309A1 (fr) 2017-09-21
CA3015309C true CA3015309C (fr) 2024-02-13

Family

ID=58715155

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3015309A Active CA3015309C (fr) 2016-03-16 2017-03-15 Composes de carbapeneme

Country Status (13)

Country Link
US (1) US11180504B2 (fr)
EP (1) EP3430013B1 (fr)
JP (1) JP7213173B2 (fr)
KR (1) KR102435777B1 (fr)
CN (1) CN109415365B (fr)
AU (1) AU2017235293B2 (fr)
BR (1) BR112018068462A2 (fr)
CA (1) CA3015309C (fr)
IL (1) IL261782B1 (fr)
MA (1) MA43791A (fr)
MX (1) MX2018011095A (fr)
WO (1) WO2017158616A1 (fr)
ZA (1) ZA201805158B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020027553A1 (fr) * 2018-08-03 2020-02-06 한양대학교 에리카산학협력단 Sonde pour la détection de bactéries résistantes au carbapénème et utilisation correspondante
WO2023007325A1 (fr) * 2021-07-28 2023-02-02 University Of Kwazulu-Natal INHIBITEURS DE MÉTALLO-β-LACTAMASES
WO2023243601A1 (fr) * 2022-06-13 2023-12-21 モジュラス株式会社 Composé d'amine cyclique d'azacycloalkyle carbonyle

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4194047A (en) 1975-11-21 1980-03-18 Merck & Co., Inc. Substituted N-methylene derivatives of thienamycin
EP0017992A1 (fr) 1979-04-19 1980-10-29 Merck & Co. Inc. Acides 1-carbadéthiapén-2-èm-carboxyliques substitués en position 2 et 6, procédés pour les préparer, compositions pharmaceutiques antibiotiques les contenant et procédé pour préparer des intermédiaires
EP0044170A1 (fr) 1980-07-11 1982-01-20 Beecham Group Plc Antibiotiques bêta-lactame, leur préparation et leur utilisation
EP0059554A3 (fr) 1981-02-27 1982-10-20 Beecham Group Plc Antibiotiques bêta-lactame, un procédé pour leur préparation et leur application en compositions pharmaceutiques
JPS57158785A (en) 1981-02-27 1982-09-30 Beecham Group Ltd Beta-lactam antibiotic, manufacture and medicinal composition
CA1283906C (fr) 1983-05-09 1991-05-07 Makoto Sunagawa COMPOSE DE .beta.-LACTAM ET PROCEDE DE PRODUCTION
JPS60233076A (ja) * 1984-05-03 1985-11-19 Sumitomo Chem Co Ltd 新規なβ−ラクタム化合物およびその製造法
JPS6383062A (ja) * 1986-09-26 1988-04-13 Nippon Redarii Kk アゼチジンスルホン酸誘導体
CA2004798A1 (fr) * 1988-12-09 1990-06-09 Jacques Banville 6-aminoalkyl carbapenemes
JPH04211083A (ja) * 1990-02-23 1992-08-03 Sankyo Co Ltd カルバペネム−3−カルボン酸誘導体
JP2934283B2 (ja) * 1990-05-29 1999-08-16 第一製薬株式会社 カルバペネム誘導体
JP2559949B2 (ja) 1991-06-04 1996-12-04 三共株式会社 1−メチルカルバペネム誘導体
US5317016A (en) 1991-08-20 1994-05-31 Shionogi Seiyaku Kabushiki Kaisha Pyrrolidylthiocarbapenem derivative
GB9202298D0 (en) * 1992-02-04 1992-03-18 Ici Plc Antibiotic compounds
JP3411589B2 (ja) * 1992-05-11 2003-06-03 第一製薬株式会社 カルバペネム誘導体
US5602118A (en) 1993-03-16 1997-02-11 American Cyanamid Company 2-thiosubstituted carbapenems
JP3199300B2 (ja) 1994-05-09 2001-08-13 三共株式会社 1−メチルカルバペネム誘導体

Also Published As

Publication number Publication date
AU2017235293B2 (en) 2021-02-04
ZA201805158B (en) 2023-01-25
JP7213173B2 (ja) 2023-01-26
KR102435777B1 (ko) 2022-08-23
AU2017235293A1 (en) 2018-08-23
CN109415365A (zh) 2019-03-01
KR20180133420A (ko) 2018-12-14
WO2017158616A1 (fr) 2017-09-21
EP3430013B1 (fr) 2023-11-15
CN109415365B (zh) 2022-08-09
BR112018068462A2 (pt) 2019-01-22
MX2018011095A (es) 2019-01-10
EP3430013A1 (fr) 2019-01-23
MA43791A (fr) 2018-11-28
WO2017158616A8 (fr) 2018-06-07
JP2019512547A (ja) 2019-05-16
RU2018136064A (ru) 2020-04-16
IL261782A (en) 2018-10-31
CA3015309A1 (fr) 2017-09-21
RU2018136064A3 (fr) 2020-04-16
US20200291029A1 (en) 2020-09-17
IL261782B1 (en) 2024-03-01
US11180504B2 (en) 2021-11-23

Similar Documents

Publication Publication Date Title
ES2939775T3 (es) Macrociclos como moduladores del regulador de la conductancia transmembrana de la fibrosis quística, composiciones farmacéuticas de los mismos, su uso en el tratamiento de la fibrosis quística, y procesos para elaborarlos
AU2021203373B2 (en) MCL-1 inhibitors
CA3210224A1 (fr) Inhibiteurs de cdk et leurs procedes d'utilisation
AU2023200842A1 (en) 3-carbonylamino-5-cyclopentyl-1H-pyrazole compounds having inhibitory activity on CDK2
ES2526202T3 (es) Inhibidores heterocíclicos de la janus cinasa 3
CA3071143A1 (fr) Nouveaux composes
CA3078195A1 (fr) Nouveaux composes de sulfonamide carboxamide
AU2003235741B2 (en) Deazapurines and uses thereof
US20210130329A1 (en) Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
US20190225611A1 (en) Substituted spirocyclic inhibitors of autotaxin
CN110382515A (zh) 经修饰的环状二核苷酸化合物
AU2023248127A1 (en) Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same
CA3015309C (fr) Composes de carbapeneme
CA3206117A1 (fr) Conjugue a substance bioactive, son procede de preparation et son utilisation
AU2019331993B2 (en) Highly active sting protein agonist compound
UA126000C2 (uk) Хроманмонобактамові сполуки для лікування бактеріальних інфекцій
CA2908575A1 (fr) Macrolides et leurs procedes de preparation et d'utilisation
TW202136239A (zh) 用於治療與sting活性相關之病狀的化合物及組合物
ES2944658T3 (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de PI3Kdelta
ES2740224T3 (es) 6H-isocromeno[3,4-c]piridinas y benzo[c][1,7]naftiridin-6-(5H)-onas como inhibidores de la cinasa asociada a adaptador 1 (AAK1)
CS226025B2 (en) Method of preparing cephalosporine derivatives
HU191066B (en) Process for preparing carbapenem derivatives
FI96311C (fi) Menetelmä farmaseuttisesti käyttökelpoisten 6-(1-hydroksietyyli)-3-(substituoitu tio)-7-okso-1-atsabisyklo/3.2.0/hept-2-eeni-2-karboksyylihappojohdannaisten valmistamiseksi
RU2772909C2 (ru) Карбапенемовые соединения
EA044967B1 (ru) Макроциклы в качестве модуляторов муковисцидозного трансмембранного регулятора проводимости, их фармацевтические композиции, применение их для лечения муковисцидоза и способ их изготовления

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314